Recently, Fujifilm Corporation announced a $188 million investment to build a cell culture media manufacturing facility
in Research Triangle Park (RTP) in North Carolina, USA.
The new facility will be operated by Fujifilm Irving Technology, a subsidiary of Fujifilm Corporation, a high-tech company
that develops and delivers advanced cell culture solutions for life science research, bioproduction, cell and gene therapy and medical applications.
The new facility is designed to enable Fujifilm Irving Technologies to help meet the growing demand
for high-quality cell culture media solutions.
Land development and construction of the plant is scheduled to begin in spring 2023, while operations
will begin in 2025.
It is understood that in recent years, with the wave of innovation in the pharmaceutical industry, many enterprises are accelerating the construction of new R&D and production base projects
in order to improve profitability, enhance innovative R&D capabilities, supplement product lines, and improve industrial layout.
Among them, Chinese pharmaceutical companies are very active
in this regard.
On November 23, Yibai Pharmaceutical issued an announcement that the company's anti-tumor drug expansion project was completed and began trial production, and the total investment in fixed assets of the project is expected to be 603 million yuan
.
According to the announcement, the "Meian Science and Technology New City New Factory Construction Project" invested and constructed by Hainan Changan International Pharmaceutical Co.
, Ltd.
, a wholly-owned subsidiary of Yibai Pharmaceutical, has completed the main construction of the project and the installation and commissioning of equipment, and the project has met the conditions for trial production and officially entered the trial production stage
.
Yibai Pharmaceutical said that the commissioning of the project is conducive to improving the company's R&D production efficiency, improving the company's product quality, expanding the company's product scale, further enhancing the company's product market competitiveness, laying a new foundation for the company's future product research and development, pilot and production, and promoting the company's strategic goal
of long-term healthy and sustainable development.
On November 16, Erkang Pharmaceutical announced that the company will use self-financing of 1 billion yuan to invest in the construction of lithium carbonate and its preparation projects, mainly in Liuyang Economic and Technological Development Zone, and the construction period (including commissioning) is expected to be 6 months
.
Erkang Pharmaceutical is the main construction body
of this lithium carbonate and its preparation project.
Of the RMB1 billion investment arrangement, RMB400 million is construction investment, of which RMB100 million is spent on construction projects, RMB260 million on equipment purchase, RMB40 million on installation projects, and RMB600 million is working capital
.
According to the announcement, the lithium carbonate and its preparation project includes three major contents
: the expansion of the preparation workshop, the construction of a new lithium carbonate raw material production workshop, and the transformation of the warehouse and sewage treatment station.
Among them, the expansion of the preparation workshop is the powder packaging area, tablet granulation area, tablet pressing area, tablet coating area and tablet packaging area, and the expansion has an annual production capacity
of 47 million bags of powder and 5 billion tablets.
.
.
.
.
.
.
It is worth mentioning that there are also multinational pharmaceutical companies that are also investing heavily in China to build new projects
.
For example, AstraZeneca has been continuously increasing investment in recent years and deepening its layout
in China.
On the first day of this year's Expo, AstraZeneca announced that it would further deepen cooperation with the Qingdao Municipal Government of Shandong Province, establish an inhalation aerosol plant in Qingdao High-tech Zone, support Qingdao to build a leading innovation highland for rare disease diagnosis and treatment in China, and set up Qingdao Smart Medical Innovation Center and Qingdao International Life Science Innovation Park
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
